20Aug 2017

ABSTRACT: Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet this challenge, we have developed a local prolonged siRNA delivery system (Local Drug EluteR, LODER) shedding siRNA against the mutated KRAS (siG12D LODER). The siG12D LODER was assessed for its structural, release, and delivery properties in vitro and in vivo. The effect of the siG12D LODER on tumor growth was assessed in s.c. and orthotopic mouse models. KRAS silencing effect was further assessed on the KRAS downstream signaling pathway. The LODER-encapsulated siRNA was stable and active in vivo for 155 d. Treatment of PDA cells with siG12D LODER resulted in a significant decrease in KRAS levels, leading to inhibition of proliferation and epithelial–mesenchymal transition. In vivo, siG12D LODER impeded the growth of human pancreatic tumor cells and prolonged mouse survival. We report a reproducible and safe delivery platform based on a miniature biodegradable polymeric matrix, for the controlled and prolonged delivery of siRNA. This technology provides the following advantages: (i) siRNA is protected from degradation; (ii) the siRNA is slowly released locally within the tumor for prolonged periods; and (iii) the siG12D LODER elicits a therapeutic effect, thereby demonstrating that mutated KRAS is indeed a druggable target.

2013 Zorde Khvalevsky Silenseed pre-clinical PNAS

31Jul 2017

Talia Golan, Elina Zorde Khvalevsky, Ayala Hubert, Rachel Malka Gabai, Naama Hen, Amiel Segal, Abraham Domb, Gil Harari, Eliel Ben David, Stephen Raskin, Yuri Goldes, Eran Goldin, Rami Eliakim, Maor Lahav, Yael Kopleman, Alain Dancour, Amotz Shemi and Eithan Galun, Oncotarget May 19, 2015

ABSTRACT

Purpose: The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor and released a siRNA drug against KRAS(G12D) along four months. This novel siRNA based drug was studied, in combination with chemotherapy, as targeted therapy for Locally Advanced Pancreatic Cancer (LAPC).

Methods: An open-label Phase 1/2a study in the first-line setting of patients with non-operable LAPC was initiated. In this study patients were assigned to receive a single dose of siG12D-LODERs, in three escalating dose cohorts (0.025mg, 0.75mg and 3.0mg). Gemcitabine was given on a weekly basis, following the siG12D-LODERTM insertion, until disease progression. The recommended dose was further examined with modified FOLFIRINOX. The follow up period was eight weeks and survival until death.

View PDF
Read More

31Jul 2017

Ramot Y, Rotkopf S, Gabai RM, Khvalevsky EZ, Muravnik S, Marzoli GA, Domb AJ, Shemi A, Nyska A.

Abstract: Conventional chemotherapy treatments for pancreatic cancer are mainly palliative. RNA interference (RNAi)-based drugs present the potential for a new targeted treatment. LOcal Drug EluteR (LODERTM) is a novel biodegradable polymeric matrix that shields drugs against enzymatic degradation and releases small interfering RNA (siRNA) against G12D-mutated KRAS (siG12D). siG12D-LODER has successfully passed a phase 1/2a clinical trial. Such a formulation necessitates biocompatibility and safety studies. We describe the safety and toxicity studies with siG12D-LODER in 192 Hsd:Sprague Dawley rats, after repeated subcutaneous administrations (days 1, 14, and 28). Animals were sacrificed on days 29 and 42 (recovery phase). In all groups, no adverse effects were noted, and all animals showed favorable local and systemic tolerability. Histopathologically, LODER implantation resulted in the expected capsule formation, composed of a thin fibrotic tissue. On the interface between the cavity and the capsule, a single layer composed of macrophages and multinucleated giant cells was observed. No difference was noted between the placebo and siG12D-LODER groups. These findings provide valuable information for future preclinical studies with siRNA-bearing biodegradable polymers and for the safety aspects of RNAi-based drugs as a targeted therapy.

View PDF
Read More

31Jul 2017

Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai, Abraham Domb, Yechezkel Barenholz, Oncotarget , Sep 22, 2015

Abstract: The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offers an alternative to both systemic delivery and intratumoral injection. Presented here is a model of drug distribution from such a source, in a multistep process. At delivery onset the drug mainly affects the closest surroundings. Such ‘priming’ enables drug penetration to successive cell layers. Tumor ‘void volume’ (volume not occupied by cells) increases, facilitating lymphatic perfusion. The drug is then transported by hydraulic convection downstream along interstitial fluid pressure (IFP) gradients, away from the tumor core. After a week tumor cell death occurs throughout the entire tumor and IFP gradients are flattened. Then, the drug is transported mainly by ‘mixing’, powered by physiological bulk body movements. Steady state is achieved and the drug covers the entire tumor over several months. Supporting measurements are provided from the LODER™ system, releasing siRNA against mutated KRAS over months in pancreatic cancer in-vivo models. LODER™ was also successfully employed in a recent Phase 1/2 clinical trial with pancreatic cancer patients.

View PDF
Read More

31Jul 2017

Richard A. Stein. Genetic Engineering & Biotechnology News. 2017.
An advantage of the LODER platform is that it delivers RNAi locally, within the tumor, Circumventing systemic toxicity and the need for large systemically administered doses.
“We have preclinical and clinical data showing that our treatment is safe,” asserts Dr. Shemi. “It affects the development of tumors and impedes the development of new metastases.”

Unpublished preclinical studies show that Loder may be used in combination with immune-oncology treatments. “We strongly believe that this combination can open new markets for many companies for treating pancreatic cancer and possibly other solid tumors,” comments Dr. Shemi.

Read More

31Jul 2017

Ricardo Titze-de-Almeida, Catherine David & Simoneide Souza Titze-de-Almeida. Pharmaceutical Research. 2017.

“siG12D-LODER made KRAS a druggable anticancer target. New drugs also targeting this oncogene are now in test and may represent future competitors of siG12D-LODER. siG12D-LODER is the only RNAi-based drug that provides a sustained release of siRNA into the tumor region thanks to a well-known biodegradable PLGA polymer, approved by FDA for drug delivery.
This siRNA represents a hopeful strategy against advanced pancreatic cancer…. Taking the aggressive behavior of pancreatic tumor cells, siG12DLODER is a promising anticancer therapy.
Results of a phase 1/2a was positive in a relatively small number of patients, so we must wait for an ongoing phase 2 study that is testing siG12DLoder (2.8 mg) plus standard chemotherapy for patients with unresectable advanced pancreatic cancer”

Read More

 

31Jul 2017

Benjamin A. Krantz, Kenneth H. Yu, Eileen M. O’Reilly.

Chinese Clinical Oncology. 2017.

“Targeting RAS by inhibiting
translation using small-interfering RNAs is a novel strategy
to decrease RAS activity. siRNA against the G12D mutant
RAS RNA by local prolonged delivery, siG12D LODER
(Local Drug EluteR), has demonstrated decreased growth of
human pancreatic tumor cells in vivo and prolonged mouse
survival. In a phase Ib/II dose escalation 15 locally
advanced, unresectable patients received siG12D LODER
with a mOS of 15.12 months. Ten out of 12 patients
had SD on repeat imaging and 2 had a PR.”

Read More

31Jul 2017
Silenseed Phase II pancreatic cancer drug -Amotz Shemi

Israeli drug development company Silenseed is to begin a Phase II multicenter trial for its pancreatic cancer treatment. The study, which has been approved by the US Food and Drug Administration (FDA), will be held at several leading medical centers in the US with the participation of 80 patients. At the same time, the Modi’in based company is raising $10 million in order to help conduct the trial. To date, Silenseed has raised $10 million, mainly from private investors, including leading Israeli cancer researchers.

Silenseed’s drug is based on siRNA, a promising technology which has yet to be translated into an effective treatment. siRNA has been marked out as a potential new family of drugs compared with most treatments today which are based on proteins or protein agents. siRNA prevents the decoding of certain proteins from a gene called KRAS, which creates a mutation that becomes a cancerous cell.

the slow progress made by siRNA technology stems among other things through the difficulty of delivering the RNA to the right place in the body and into the cell because it breaks up so easily.

Read More

  • 1
  • 2